J 2009

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

MRÁZ, Marek, Karla MALINOVÁ, Jana KOTAŠKOVÁ, Šárka PAVLOVÁ, Boris TICHÝ et. al.

Basic information

Original name

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

Authors

MRÁZ, Marek (203 Czech Republic, belonging to the institution), Karla MALINOVÁ (203 Czech Republic, belonging to the institution), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Kateřina STAŇO KOZUBÍK (203 Czech Republic, belonging to the institution), Jana ŠMARDOVÁ (203 Czech Republic), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Leukemia, Stockton Press, 2009, 0887-6924

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 8.296

RIV identification code

RIV/00216224:14110/09:00067111

Organization unit

Faculty of Medicine

UT WoS

000266820700018

Keywords in English

CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSION; MICRORNAS

Tags

International impact, Reviewed
Changed: 26/4/2014 11:04, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course. CLL can be classified into two biological subtypes, according to the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgVH). IgVH mutational status is of high-clinical relevance: cases with unmutated IgVH show a less favorable course with a rapid progression, whereas cases with mutated IgVH show a stable disease and longer survival. Unfavorable prognosis is also associated with the inactivation of an important tumor-suppressor p53; these patients harbor a deletion of 17p13 and this chromosomal abnormality is often accompanied by the mutation of the second TP53 allele, which leads to the complete elimination of p53 function. Moreover, a single mutation of one of the TP53 allele also occurs in a significant proportion of CLL cases. Patients with TP53 abnormalities typically do not respond to therapy and have a median survival of less than 3 years.